3 Outperforming Biotech Stocks With Further Upside In The Back Half Of 2021

Looking at the biotech sector right now, new drug approvals could gain momentum in the wake of the FDA’s approval of Biogen’s Alzheimer’s drug, mergers and acquisitions are expected to pick up as the big players in the sector look to bolster their portfolios and pipelines and, of course, the development of coronavirus vaccines and treatments remains the underlying story. Against this backdrop, the author of today’s article highlights “three biotech companies, which have outperformed the sector in the year so far and still hold enough room for an upside, backed by strong fundamentals.” For these three biotech stocks, CLICK HERE.